BioSpace News Archive

InMode Ltd today announced that Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present in-person at the Jefferies Healthcare Conference in New York on June 5, 2024.

CinDome Pharma, a CinRx portfolio company dedicated to advancing a safe, chronic therapy for gastroparesis, today announced a $40 million Series B financing extension.

Nutcracker Therapeutics, Inc. today announced it will introduce its new preclinical drug candidate, NTX-472, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago.

Avenue Therapeutics, Inc. today announced the completion of the last patient’s final visit in the Company’s Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (“SBMA”), also known as Kennedy’s Disease.

Nuvectis Pharma, Inc. today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 2nd BioConnect Investor Conference at the NASDAQ world headquarters in New York City.

Moleculin Biotech, Inc. today announced its abstract has been accepted for poster presentation at the EHA2024 Hybrid Congress being held June 13-16, 2024 in Madrid, Spain and virtually.

Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2024 Jaws and Paws Conference on Wednesday, May 29, 2024. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 12:05 p.m. ET.

NanoVibronix, Inc., a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave Portable Ultrasonic Therapeutic Devices, issued a letter to its stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the first quarter of 2024 and recent business developments.

ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy, today announced results for the first quarter ended March 31, 2024.

MAIA Biotechnology, Inc. today announced that an abstract about its Phase 2 THIO-101 clinical trial named “ A phase 2, multicenter, open-label, dose-optimization study evaluating telomere-targeting agent THIO was accepted for poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, to take place May 31-June 4, 2024, in Chicago, Illinois.